HEALTH

Kline Group: 2015 OTC sales up, but marketing support may be waning

BY DSN STAFF
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
HEALTH

Endo names Campanelli president, CEO

BY David Salazar
DUBLIN — Endo has a new president and CEO. The company announced Tuesday that its board of directors had named Paul Campanelli to the position, effective immediately, succeeding Ravid De Silva, who has stepped down from the position and his place on the company's board of directors.
 
“I am very excited to lead Endo at this important time and, together with a strong senior management team, address the challenges of today's healthcare environment,” Campanelli said.  “I look forward to working closely and collaboratively with our leadership team and Endo's Board to build on our strengths and help position the company to thrive over the long-term.”
 
Campanelli takes the reigns at Endo from his position as president of its generic and OTC business Par Pharmaceutical, which makes up about 60% of Endo’s total revenue. He had been Par’s CEO from 2012 until the company was acquired by Endo in 2015. During his time at the head of Par, the company grew its total revenue, acquired JHP Pharmaceuticals and established itself in the European generics market. 
 
“Given the continued evolution of Endo's business and Paul's impressive track record of delivering strong operating results, the Board concluded that Paul is the right leader for Endo at this juncture as we focus on execution and increasing the value of our attractive U.S. Branded, U.S. Generic and International pharmaceutical assets,” Endo board chairman Roger Kimmel said. “The Board believes his experience positions him to drive a broad range of growth initiatives across Endo's entire portfolio, generating better health outcomes for patients and creating value for Endo's shareholders.”
 
Alongside the announcement, Endo affirmed its guidance for the third quarter and full-year, expecting Q3 revenues between $830 million and $870 million and full-year revenues of between $3.87 billion and $4.03 billion. 
 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
HEALTH

Puerto Rico reconsiders dietary supplement Administrative Order 346

BY Michael Johnsen

WASHINGTON — The Puerto Rico Secretary of Health, Ana Ríus Armendáriz, announced this week that the Department of Health will not enforce Administrative Order 346, which placed regulatory fees on the distribution and manufacturing of dietary supplements that industry described as burdensome, advising she will now go through proper channels of notice, including a hearing, followed by a comment and rule making period later this year.

“We’re very encouraged that the Secretary is open to dialoguing with businesses and industry about this situation," stated Mike Greene VP government relations at the Council for Responsible Nutrition. "AO 346 would have a detrimental effect, both on consumers, who would be faced with higher prices on supplement products that are important for their health, and on businesses that contribute to the local economy," he said.

"We understand there are concerns about dangerous spiked products being illegally sold as dietary supplements, and we share that concern. It’s important, however, to separate the legitimate industry that manufactures and markets healthful products, such as multivitamins, calcium [and] fish oil … from those companies that are selling products that are illegal drugs, not legal dietary supplements," Greene added.
 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?